Wednesday, February 12, 2025
spot_img

Logansport Financial Corp. Reports Earnings for the Three and Twelve Months Ended December 31, 2024

LOGANSPORT, Ind., Feb. 12, 2025 (GLOBE NEWSWIRE) — Logansport Financial Corp., (OTCBB: LOGN), parent company of Logansport Savings Bank, reported net earnings for the three and twelve months ended December 31, 2024.

Net earnings for the three months ended December 31, 2024 totaled $445,000, compared to the $295,000 in net earnings reported for the three months ended December 31, 2023.

Net earnings for the year ended December 31, 2024 totaled $1,254,000, compared to the $1,791,000 reported for the year ended December 31, 2023. Earnings per share was $2.05 for December 31, 2024, compared to $2.93 for December 31, 2023. Return on Assets finished the year at 0.475% for 2024 compared to 0.723% for 2023. The Return on Equity finished the year at 6.14% for December 31, 2024, compared to 8.65% for December 31, 2023.

The statements contained in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involves a number of risks and uncertainties. A number of factors could cause results to differ materially from the objectives and estimates expressed in such forward-looking statements. These factors include, but are not limited to, changes in the financial condition of issuers of the Company’s investments and borrowers, changes in economic conditions in the Company’s market area, changes in policies of regulatory agencies, fluctuations in interest rates, demand for loans in the Company’s market area, changes in the position of banking regulators on the adequacy of our allowance for loan losses, and competition, all or some of which could cause actual results to differ materially from historical earnings and those presently anticipated or projected. These factors should be considered in evaluation of forward-looking statements, and undue reliance should not be placed on such statements. The Company does not undertake and specifically disclaims any obligation to update any forward-looking statements to reflect occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

Logansport Financial Corp.
Selected Financial Data
(Dollars in thousands except for share data)
         
       
    12/31/2024 12/31/2023  
         
Total Assets   $263,860 $247,713  
         
Loans receivable, net     175,742   168,672  
Allowance for loan losses     1,954   2,553  
Cash and cash equivalents     14,992   4,810  
Interest Bearing Time Deposits in banks        
Securities available for sale     54,567   59,404  
Federal Home Loan Bank stock     3,082   3,082  
Deposits     225,904   207,779  
FHLB borrowings and note payable     15,000   15,000  
Accrued Interest and other liabilities     2,525   2,266  
Shareholders’ equity     20,431   20,717  
Shares Issued and Outstanding     611,597   611,334  
Nonperforming loans     2,907   504  
Real Estate Owned        
         

 

           Three months ended 12/31          Year ended 12/31  
      2024   2023     2024     2023  
               
Interest income   $3,559 $3,254   $12,981   $11,967  
Interest expense     1,552   1,554     6,209     4,897  
Net interest income     2,007   1,700     6,772     7,070  
Provision for loan losses           (79 )    
Net interest income after provision     2,007   1,700     6,851     7,070  
Gain on sale of loans     133   36     393     170  
Other income     211   179     999     1,018  
General, admin. & other expense     1,797   1,580     6,968     6,247  
Earnings before income taxes     554   335     1,275     2,011  
Income tax expense     109   40     21     220  
Net earnings   $445 $295   $1,254   $1,791  
 
Earnings per share         $2.05   $2.93  
Weighted avg. shares o/s-diluted           608,124     608,272  
                     

Contact: Kristie Richey
Chief Financial Officer
Phone-574-722-3855
Fax-574-722-3857

Powered by SlickText.com

Hot this week

Rexel: Q4 sales & FY 2024 results

 Q4 sales & FY 2024 resultsSales & Ebita margin...

KLÉPIERRE: STRONG 2024 OUTPERFORMANCE WITH POSITIVE OUTLOOK FOR 2025

PRESS RELEASE STRONG 2024 OUTPERFORMANCE WITH POSITIVE OUTLOOK...

FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)

Evrysdi is the only non-invasive disease-modifying SMA treatment and...

McPhy Energy: Financial calendar for 2025

Foussemagne (France), on February 12, 2025 – 5:45 pm...

Topics

spot_img

Related Articles

Popular Categories

spot_img